Both RAC1-specific and dual RAC1/CDC42 inhibitors (NSC23766 and AZA1, respectively) have shown preclinical efficacy in prostate cancer cell lines (including PTEN-null PC-3 cells), inhibiting both cell migration and in vivo tumor growth [288,289]. This evidence concerns the gene PTEN and prostate carcinoma.